Palvella Therapeutics, Inc. (PVLA) Receivables (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Receivables for 11 consecutive years, with $373000.0 as the latest value for Q3 2024.
- On a quarterly basis, Receivables fell 64.31% to $373000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $373000.0, a 64.31% decrease, with the full-year FY2023 number at $3.1 million, down 49.92% from a year prior.
- Receivables was $373000.0 for Q3 2024 at Palvella Therapeutics, down from $4.5 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $17.0 million in Q2 2021 to a low of $373000.0 in Q3 2024.
- A 5-year average of $5.3 million and a median of $3.1 million in 2023 define the central range for Receivables.
- Peak YoY movement for Receivables: skyrocketed 477.45% in 2021, then tumbled 95.12% in 2022.
- Palvella Therapeutics' Receivables stood at $1.7 million in 2020, then skyrocketed by 94.2% to $3.3 million in 2021, then surged by 89.31% to $6.3 million in 2022, then tumbled by 49.92% to $3.1 million in 2023, then crashed by 88.12% to $373000.0 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Receivables are $373000.0 (Q3 2024), $4.5 million (Q2 2024), and $4.2 million (Q1 2024).